Vescap Capsule 1 gm
Vescap Capsule 1 gm Uses, Dosage, Side Effects, Food Interaction and all others data.
Vescap Capsule 1 gm or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL). FDA approved on July 26, 2012.
| Trade Name | Vescap Capsule 1 gm |
| Generic | Icosapent ethyl |
| Icosapent ethyl Other Names | E-EPA, Eicosapentaenoic acid ethyl ester, Ethyl eicosapentaenoate, Ethyl icosapentate, Ethyl-EPA, Icosapent ethyl, Timnodonic acid ethyl ester |
| Weight | 1 gm |
| Type | Capsule |
| Formula | C22H34O2 |
| Weight | Average: 330.5042 Monoisotopic: 330.255880332 |
| Groups | Approved, Investigational, Nutraceutical |
| Therapeutic Class | |
| Manufacturer | Ziska Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Vescap Capsule 1 gm is an ethyl ester of eicosapentaenoic acid (EPA) that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia.
Vescap Capsule 1 gm is used as adjunct therapy to reduce triglyceride (TG) levels in adults with severe (>500 mg/dL) hypertriglyceridemia.
Vescap Capsule 1 gm is also used to associated treatment for these conditions: Severe Hypertriglyceridemia
How Vescap Capsule 1 gm works
Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.
Toxicity
Vescap Capsule 1 gm is generally well tolerated and adverse effects are unrelated to treatment.
Food Interaction
- Take with food.
Volume of Distribution
Steady state volume of distribution of active EPA is 88 L
Elimination Route
Vescap Capsule 1 gm is de-esterfied, converted into active EPA, and then absorbed in the small intestine. It reaches peak plasma concentration in 5 hours post-oral administration. Very little (<1%) is left circulating in the plasma as EPA incorporates into phospholipids, TG's, and cholesteryl esters.
Half Life
The half life of EPA is 89 hours.
Clearance
Total plasma clearance, EPA = 684 mL/hr
Elimination Route
Vescap Capsule 1 gm is not renally excreted
Innovators Monograph
You find simplified version here Vescap Capsule 1 gm
